Healthcare company partners with three European medical laboratories for more than 30 orders of self-operating blood-drawing equipment
In the ever-evolving world of medical technology, BHealthCare, a pioneering MedTech company based in Europe, is making significant strides with its innovative autonomous blood drawing device, HEIVA.
BHealthCare, one of the first companies in Europe and among a select few globally, is offering this groundbreaking technology. HEIVA is designed to autonomously draw blood samples from thousands of daily patients at selected major European medical laboratory groups, marking a significant leap in medical automation.
The company is currently in the midst of a fundraising round, with the aim of completing HEIVA's pivotal clinical trial and launching its industrial manufacturing process. However, the exact amount of funds raised or the specific details about the device have not been disclosed in the latest article from "Digital Health & AI Insights".
HEIVA has already achieved the CE mark, indicating it meets the necessary regulatory requirements for medical devices in Europe. It has also secured approval for use in the GCC (Gulf Cooperation Council) countries, allowing its deployment in Middle Eastern markets. As of now, HEIVA is commercially available and being marketed in both Europe and the Middle East.
BHealthCare has secured among its pre-orders one of its biggest supplier agreements to date and counts European market leaders among its growing list of customers. The company has announced supply agreements with three European medical biology laboratories for pre-orders of HEIVA.
Despite the ongoing fundraising efforts, the article in "Digital Health & AI Insights" does not mention the industrial manufacturing process for HEIVA. The company anticipates obtaining CE marking for HEIVA next year.
BHealthCare was founded in late 2016 and has raised 13.5 million EUR (15M USD) in capital funds and grants since then. The company specializes in autonomous robotic solutions for peripheral vascular access.
The development of HEIVA began in 2020, with the prototype undergoing pilot clinical evaluation. The latest article in "Insights" does not mention the pilot clinical evaluation of HEIVA.
In other news, the EU is currently discussing cybersecurity measures for medtech, as discussed in another article titled "Insights". This discussion underscores the importance of ensuring the security of medical technologies like HEIVA as they become more integrated into our healthcare systems.
As BHealthCare continues to push the boundaries of medical technology, the future of autonomous blood drawing devices like HEIVA promises to be an exciting one.
- BHealthCare's autonomous blood drawing device, HEIVA, is revolutionizing patient care, particularly in Europe and GCC countries, by automating blood sample collection from numerous daily patients.
- In the realm of digital health, BHealthCare showcases its innovative approach by developing cutting-edge technology like HEIVA, which not only furthers science in medical-conditions management but also aligns with the broader health-and-wellness and technology movements.
- BHealthCare is in the fundraising stage to fund the pivotal clinical trial for HEIVA and commence its industrial manufacturing process. Although the exact funds raised remain undisclosed in recent reports from "Digital Health & AI Insights", the company has raised significant capital since it was founded in late 2016.
- As BHealthCare expands its business operations, it has engaged in pre-orders and secured important supplier agreements, partnering with European market leaders such as three major medical biology laboratories for future sales of HEIVA. With the company's continuing development, the budding market for digital health solutions like HEIVA is poised for substantial growth within the finance and technology sectors.
